Literature DB >> 2437969

Role of 4-hydroxylated estradiol in reducing Ca2+ uptake of uterine arterial smooth muscle cells through potential-sensitive channels.

S L Stice, S P Ford, J P Rosazza, D E Van Orden.   

Abstract

Entry of ionic Ca2+ into the vascular smooth muscle cell for contraction is thought to be mediated by two major membrane channels. The first are designated as potential-sensitive channels (PSCs), which are opened by membrane depolarization, and the second, as receptor-operated channels (ROCs), which are activated by alpha 1-receptor-ligand interactions. This study was designed to determine the presence of these 2 distinct populations of Ca2+ entry channels in smooth muscle cells of the uterine arteries in pigs. This was studied by measuring the baseline tone and contractile properties of uterine arteries in in vitro perfusion studies, as well as their specific Ca2+ uptakes. These parameters showed markedly different sensitivities towards two smooth muscle inhibitors used in this study: D-600 and amrinone. D-600 specifically inhibits uptake of extracellular Ca2+ through PSCs, while amrinone specifically inhibits Ca2+ uptake through ROCs. By choosing an appropriate concentration of D-600 or amrinone, Ca2+ uptake and contractions of uterine arterial segments induced by high-K+ (PSC activator) and phenylephrine (ROC activator) could be selectively inhibited. Furthermore, it was demonstrated that the blockade of Ca2+ uptake by D-600 and amrinone was additive, excluding the interpretation of a common Ca2+ pathway with two separate mechanisms for opening it. It was also determined that 4-hydroxylated estradiol (4OH-E2), a compound known to increase uterine blood flow in pigs, decreased Ca2+ uptake through the PSCs and exhibited no effect on ROCs. The presence of separate Ca2+ pathways that can be activated independently by agonists may indicate a refined system for controlling uterine blood flow.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437969     DOI: 10.1095/biolreprod36.2.361

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  9 in total

1.  Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation.

Authors:  C R Rosenfeld; B E Cox; T Roy; R R Magness
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

Review 2.  Cardiovascular pharmacology of hormone replacement therapy.

Authors:  G M Rosano; G Panina
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  Investigation of the negative inotropic effects of 17 beta-oestradiol in human isolated myocardial tissues.

Authors:  G Sitzler; O Lenz; H Kilter; K La Rosee; M Böhm
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  Oestradiol-induced relaxation of rabbit basilar artery by inhibition of voltage-dependent Ca channels through GTP-binding protein.

Authors:  R Ogata; Y Inoue; H Nakano; Y Ito; K Kitamura
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  Effect of acute and long-term treatment with 17-beta-estradiol on the vasomotor responses in the rat aorta.

Authors:  H L Andersen; J U Weis; B Fjalland; N Korsgaard
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 6.  Nongenomic action of steroids in myometrial contractility.

Authors:  M Perusquía
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

7.  Effect of 17 beta-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes.

Authors:  C Jiang; P A Poole-Wilson; P M Sarrel; S Mochizuki; P Collins; K T MacLeod
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

8.  Endothelium-independent relaxation of rabbit coronary artery by 17 beta-oestradiol in vitro.

Authors:  C W Jiang; P M Sarrel; D C Lindsay; P A Poole-Wilson; P Collins
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

Review 9.  Ovarian sex steroids and atherosclerosis.

Authors:  M Riedel; W Rafflenbeul; P Lichtlen
Journal:  Clin Investig       Date:  1993-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.